Different batches [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-03-08 10:19 (365 d 12:27 ago) – Posting: # 21225
Views: 2,612

Hi Marcelo,

» I agree with you. It was just a suggestion based on our previous experience in Brazil :-|. Sometimes we need to explain the inexplicable to health authority to avoid delays in the dossier review :-D

The use of a different batch in the fed study as asked above from taiyab.jameel could be better as you can prove batches therpeutic equivalence consistency via in vivo studies.

On the contrary, in the case of additional strength biowaiver, it is a must to use the same biobatch for which the therpeutic equivalence was proven before via in vivo BE study.

Best regards,


Complete thread:

 Admin contact
21,371 posts in 4,463 threads, 1,495 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time: Monday 22:46 CET (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz